Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3704)
All Articles published online
|
Jan 14, 2006 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, Aso K, Hasegawa T, Aoshima M, Miyokawa N, Haneda M, Yoneda M. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12(2): 322-326 [PMID: 16482638 DOI: 10.3748/wjg.v12.i2.322] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i2/322.htm |
| Number | Citing Articles |
| 1 |
Amal M.H. Mackawy, Mohammed E.H. Badawy, Ola Abd El-Rahman Yossef Megahed. Angiotensin converting enzyme (ACE D/I) polymorphism and its relation to liver fibrosis progression in Egyptian patients with chronic hepatitis C virus infection. Egyptian Journal of Medical Human Genetics 2012; 13(3): 291 doi: 10.1016/j.ejmhg.2012.06.006
|
| 2 |
J.S. Lubel, F.J. Warner, P.W. Angus. Frontiers in Research of the Renin-Angiotensin System on Human Disease. 2007; : 113 doi: 10.1007/978-1-4020-6372-5_6
|
| 3 |
Qiu-Zan Zhang, Ying-Li Liu, Yan-Rong Wang, Li-Na Fu, Jing Zhang, Xiu-Ru Wang, Bang-Mao Wang. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Experimental and Therapeutic Medicine 2017; 14(3): 2689 doi: 10.3892/etm.2017.4809
|
| 4 |
A. Mantovani, G. Zoppini, G. Targher, G. Golia, E. Bonora. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. Journal of Endocrinological Investigation 2012; 35(2): 215 doi: 10.1007/BF03345421
|
| 5 |
Brent A Neuschwander-Tetri. Fatty liver and the metabolic syndrome. Current Opinion in Gastroenterology 2007; 23(2): 193 doi: 10.1097/MOG.0b013e32801421a9
|
| 6 |
Nicholas W.S. Chew, Mark D. Muthiah, Arun J. Sanyal. Cardiovascular Endocrinology and Metabolism. 2023; : 137 doi: 10.1016/B978-0-323-99991-5.00003-6
|
| 7 |
Dawn M. Torres, Frances J. Jones, Janet C. Shaw, Christopher D. Williams, John A. Ward, Stephen A. Harrison. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial. Hepatology 2011; 54(5): 1631 doi: 10.1002/hep.24558
|
| 8 |
Dawn M. Torres, Stephen A. Harrison. Current treatments in nonalcoholic steatohepatitis. Current Treatment Options in Gastroenterology 2007; 10(6): 425 doi: 10.1007/s11938-007-0042-y
|
| 9 |
|
| 10 |
Erika Rabelo F Siqueira. A Review of Pharmacological Treatments of NASH. Gastroenterology & Hepatology: Open Access 2015; 2(5) doi: 10.15406/ghoa.2015.02.00058
|
| 11 |
Yuta Miyaoka, Denan Jin, Keitaro Tashiro, Shinsuke Masubuchi, Maiko Ozeki, Fumitoshi Hirokawa, Michihiro Hayashi, Shinji Takai, Kazuhisa Uchiyama. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. Experimental Animals 2018; 67(2): 239 doi: 10.1538/expanim.17-0126
|
| 12 |
Mariko Hojo, Sumio Watanabe. Pharmacological therapy of nonalcoholic steatohepatitis. Hepatology Research 2011; 41(3): 209 doi: 10.1111/j.1872-034X.2011.00780.x
|
| 13 |
Thuy-Anh Le, Rohit Loomba. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. Journal of Clinical and Experimental Hepatology 2012; 2(2): 156 doi: 10.1016/S0973-6883(12)60104-2
|
| 14 |
O. Guillaud, K.C. Gurram, M. Puglia, L. Lilly, O. Adeyi, E.L. Renner, N. Selzner. Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver Transplantation. Transplantation Proceedings 2013; 45(6): 2331 doi: 10.1016/j.transproceed.2013.01.067
|
| 15 |
Matthew J. Brookes, Tariq H. Iqbal, Brian T. Cooper. Hypertension and hepatic steatosis. Current Hypertension Reports 2008; 10(3): 182 doi: 10.1007/s11906-008-0035-9
|
| 16 |
Palanivelu Praveenraj, Rachel M. Gomes, Saravana Kumar, Purushothaman Karthikeyan, Annapoorni Shankar, Ramakrishnan Parthasarathi, Palanisamy Senthilnathan, Subbiah Rajapandian, Chinnusamy Palanivelu. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery. Obesity Surgery 2015; 25(11): 2078 doi: 10.1007/s11695-015-1655-1
|
| 17 |
Nicholas W. S. Chew, Cheng Han Ng, Mark Dhinesh Muthiah, Arun J. Sanyal. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Current Atherosclerosis Reports 2022; 24(7): 515 doi: 10.1007/s11883-022-01027-5
|
| 18 |
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertension Research 2018; 41(6): 394 doi: 10.1038/s41440-018-0040-6
|
| 19 |
Josephine A. Grace, Chandana B. Herath, Kai Yan Mak, Louise M. Burrell, Peter W. Angus. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options. Clinical Science 2012; 123(4): 225 doi: 10.1042/CS20120030
|
| 20 |
Zhaoyang Ye, Houssam S. Hajj Houssein, Ram I. Mahato. Bioconjugation of Oligonucleotides for Treating Liver Fibrosis. Oligonucleotides 2007; 17(4): 349 doi: 10.1089/oli.2007.0097
|
| 21 |
Stergios A. Polyzos, Jannis Kountouras, Christos Zavos, Eleni Tsiaousi. The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2010; 12(5): 365 doi: 10.1111/j.1463-1326.2009.01176.x
|
| 22 |
Ahad Eshraghian. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World Journal of Gastroenterology 2017; 23(42): 7495-7504 doi: 10.3748/wjg.v23.i42.7495
|
| 23 |
Kenneth Cusi. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes & Obesity 2009; 16(2): 141 doi: 10.1097/MED.0b013e3283293015
|
| 24 |
Phunchai Charatcharoenwitthaya, Jayant A. Talwalkar, Paul Angulo, Andrea A. Gossard, Jill C. Keach, Janice L. Petz, Roberta A. Jorgensen, Keith D. Lindor. Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. Digestive Diseases and Sciences 2010; 55(2): 476 doi: 10.1007/s10620-009-0744-1
|
| 25 |
Daniel R Pomaro, Francisco AH Fonseca, Anita LR Saldanha, Valeria P Lanzoni, Dulce E Casarini, Ana Paula Pantoja Margeotto, André LV , Tereza Luiza Bellincanta, Tania Leme da Rocha Martinez, Silvia SM Ihara. Diabetes and hypercholesterolemia experimental study on inhibition of liver fibrosis by angiotensin converting enzymes. Journal of Cardiology & Current Research 2021; 14(4): 107 doi: 10.15406/jccr.2021.14.00524
|
| 26 |
Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. Journal of Clinical Medicine 2021; 10(9): 2040 doi: 10.3390/jcm10092040
|
| 27 |
Eugen Florin Georgescu. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?. Advances in Therapy 2008; 25(11): 1141 doi: 10.1007/s12325-008-0110-2
|
| 28 |
Maria Soledad Rosselli, Adriana L. Burgueño, Julieta Carabelli, Mariano Schuman, Carlos J. Pirola, Silvia Sookoian. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis 2009; 206(1): 119 doi: 10.1016/j.atherosclerosis.2009.01.026
|
| 29 |
Yosui Tamaki, Yukiomi Nakade, Taeko Yamauchi, Yuichi Makino, Shiro Yokohama, Mitsuyoshi Okada, Kazunobu Aso, Hiroyuki Kanamori, Tomohiko Ohashi, Ken Sato, Haruhisa Nakao, Masakazu Haneda, Masashi Yoneda. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. Journal of Gastroenterology 2013; 48(4): 491 doi: 10.1007/s00535-012-0651-7
|
| 30 |
Simone Moreira de Macêdo, Talita Antunes Guimarães, John David Feltenberger, Sérgio Henrique Sousa Santos. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 2014; 62: 189 doi: 10.1016/j.peptides.2014.10.005
|
| 31 |
Takeshi Okanoue, Atsushi Umemura, Kohichiroh Yasui, Yoshito Itoh. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. Journal of Gastroenterology and Hepatology 2011; 26(s1): 153 doi: 10.1111/j.1440-1746.2010.06547.x
|
| 32 |
M Kamruzzman Munshi, Mohammad N Uddin, Shannon S Glaser. The role of the renin–angiotensin system in liver fibrosis. Experimental Biology and Medicine 2011; 236(5): 557 doi: 10.1258/ebm.2011.010375
|
| 33 |
Ping Lu, Hailin Liu, Hang Yin, Liu Yang. Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Medical Science Monitor 2011; 17(9): BR248 doi: 10.12659/MSM.881928
|
| 34 |
S. Kaser, C. F. Ebenbichler, H. Tilg. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. International Journal of Clinical Practice 2010; 64(7): 968 doi: 10.1111/j.1742-1241.2009.02327.x
|
| 35 |
Shahinul Alam, Mushfiqul Abrar, Saiful Islam, Mohammad Kamal, Mohammad J Hasan, Md. Abdullah S Khan, Nooruddin Ahmad. Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial. JGH Open 2020; 4(4): 663 doi: 10.1002/jgh3.12315
|
| 36 |
Claudia Della Corte, Anna Alisi, Raffaele Iorio, Arianna Alterio, Valerio Nobili. Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2011; 12(12): 1901 doi: 10.1517/14656566.2011.587123
|
| 37 |
Mariana Machado, Helena Cortez-Pinto. Non-alcoholic steatohepatitis and metabolic syndrome. Current Opinion in Clinical Nutrition and Metabolic Care 2006; 9(5): 637 doi: 10.1097/01.mco.0000241677.40170.17
|
| 38 |
Rafeeq Ali, Kenneth Cusi. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Annals of Medicine 2009; 41(4): 265 doi: 10.1080/07853890802552437
|
| 39 |
Shivakumar Chitturi. Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 2008; 1(3): 173 doi: 10.1177/1756283X08096951
|
| 40 |
MH Ahmed, CD Byrne. Drug treatment and type 2 diabetes: the impact of liver disease. Practical Diabetes International 2007; 24(6): 318 doi: 10.1002/pdi.1132
|
| 41 |
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano, Tooru Shimosegawa. Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology Research 2015; 45(4): 363 doi: 10.1111/hepr.12511
|
| 42 |
Bilal Hameed, Norah Terrault. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2016; 20(2): 365 doi: 10.1016/j.cld.2015.10.015
|
| 43 |
Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath. ACE2: from protection of liver disease to propagation of COVID-19. Clinical Science 2020; 134(23): 3137 doi: 10.1042/CS20201268
|
| 44 |
Vlad Ratziu, Maria Vispo, Mohamed Tahiri, Luminita Bonyhay, Mercedes de Torres, Carole Bernhardt, Thierry Poynard, Pascal Lebray. Peut-on traiter la stéatohépatite métabolique ?. Gastroentérologie Clinique et Biologique 2007; 31(3): 333 doi: 10.1016/S0399-8320(07)89386-9
|
| 45 |
S. Strahl, K.P. Maier. Gibt es Therapieansätze für die nicht-alkoholische Fettleber und ihre Komplikationen?. Der Internist 2008; 49(12): 1421 doi: 10.1007/s00108-008-2151-7
|
| 46 |
Vlad Ratziu, Shira Zelber-Sagi. Pharmacologic Therapy of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009; 13(4): 667 doi: 10.1016/j.cld.2009.07.001
|
| 47 |
Mark D. Muthiah, Ng Cheng Han, Arun J. Sanyal. A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know. Diabetes, Obesity and Metabolism 2022; 24(S2): 3 doi: 10.1111/dom.14521
|
| 48 |
Jewel Imani, Steven P. M. Bodine, Anthony M. Lamattina, Diane D. Ma, Shikshya Shrestha, Dawn M. Maynard, Kevin Bishop, Arinze Nwokeji, May Christine V. Malicdan, Lauren C. Testa, Raman Sood, Benjamin Stump, Ivan O. Rosas, Mark A. Perrella, Robert Handin, Lisa R. Young, Bernadette R. Gochuico, Souheil El-Chemaly. Dysregulated myosin in Hermansky-Pudlak syndrome lung fibroblasts is associated with increased cell motility. Respiratory Research 2022; 23(1) doi: 10.1186/s12931-022-02083-w
|
| 49 |
Takumi Hirata, Kengo Tomita, Toshihide Kawai, Hirokazu Yokoyama, Akira Shimada, Masahiro Kikuchi, Hiroshi Hirose, Hirotoshi Ebinuma, Junichiro Irie, Keisuke Ojiro, Yoichi Oikawa, Hidetsugu Saito, Hiroshi Itoh, Toshifumi Hibi. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). International Journal of Endocrinology 2013; 2013: 1 doi: 10.1155/2013/587140
|
| 50 |
Fiona J. Warner, John S. Lubel, Geoffrey W. McCaughan, Peter W. Angus. Liver fibrosis: a balance of ACEs?. Clinical Science 2007; 113(3): 109 doi: 10.1042/CS20070026
|
| 51 |
Keisuke Okamura, Tetsu Okuda, Yosuke Takamiya, Kazuyuki Shirai, Hidenori Urata. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart and Vessels 2019; 34(9): 1559 doi: 10.1007/s00380-019-01391-4
|
| 52 |
Amanda Ribeiro dos Santos, Aline Dionizio, Mileni da Silva Fernandes, Marília Afonso Rabelo Buzalaf, Beatriz Pereira, Débora de Fátima Almeida Donanzam, Sergio Marrone Ribeiro, Anamaria Mello Miranda Paniago, Ricardo de Souza Cavalcante, Rinaldo Poncio Mendes, James Venturini, Angel Gonzalez. Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel. PLOS Neglected Tropical Diseases 2021; 15(8): e0009714 doi: 10.1371/journal.pntd.0009714
|
| 53 |
Carlo Fabris, Carlo Smirne, Stefano Fangazio, Pierluigi Toniutto, Michela Burlone, Rosalba Minisini, Davide Bitetto, Edmondo Falleti, Andrea Cerutti, Mario Pirisi. Influence of angiotensin‐converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatology Research 2009; 39(8): 795 doi: 10.1111/j.1872-034X.2009.00518.x
|
| 54 |
Marko Duvnjak, Neven Baršić, Vedran Tomašić, Ivan Lerotić. Genetic polymorphisms in non-alcoholic fatty liver disease: Clues to pathogenesis and disease progression. World Journal of Gastroenterology 2009; 15(48): 6023-6027 doi: 10.3748/wjg.15.6023
|
| 55 |
Mariana Verdelho Machado, Anna Mae Diehl. Zakim and Boyer's Hepatology. 2018; : 369 doi: 10.1016/B978-0-323-37591-7.00025-2
|
| 56 |
Kwang Yong Shim, Young Woo Eom, Moon Young Kim, Seong Hee Kang, Soon Koo Baik. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. The Korean Journal of Internal Medicine 2018; 33(3): 453 doi: 10.3904/kjim.2017.317
|
| 57 |
Yasuhiro Miyake, Kazuhide Yamamoto. Role of gut microbiota in liver diseases. Hepatology Research 2013; 43(2): 139 doi: 10.1111/j.1872-034X.2012.01088.x
|
| 58 |
Ramesh P Thylur, Sanjit K Roy, Anju Shrivastava, Thomas A LaVeist, Sharmila Shankar, Rakesh K Srivastava. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma . JGH Open 2020; 4(3): 351 doi: 10.1002/jgh3.12336
|
| 59 |
Jung Gyu Park, Jong Soo Mok, Young In Han, Tae Sub Park, Keon Wook Kang, Cheol Soo Choi, Hee Dong Park, Joonghoon Park. Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-40322-1
|
| 60 |
J. K. Dowman, M. J. Armstrong, J. W. Tomlinson, P. N. Newsome. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011; 13(8): 692 doi: 10.1111/j.1463-1326.2011.01403.x
|
| 61 |
Mohsen Arabi, Raheleh Alimoradzadeh, Alireza Makian, Seyed Javad Shariat Nabavi, Farshad Divsalar, Mitra Kazemi Jahromi. Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review. Journal of Health Reports and Technology 2022; 8(3) doi: 10.5812/jhrt-119454
|
| 62 |
Lindsey J. Reese, Diane S. Tider, Alicia C. Stivala, Dawn A. Fishbein. Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection. AIDS Research and Treatment 2012; 2012: 1 doi: 10.1155/2012/978790
|
| 63 |
Toshiya Machida, Taku Obara, Makoto Miyazaki, Jun Inoue, Nariyasu Mano. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. Annals of Hepatology 2022; 27(4): 100699 doi: 10.1016/j.aohep.2022.100699
|
| 64 |
Ka-Kit Li, James Neuberger. Recurrent nonviral liver disease following liver transplantation. Expert Review of Gastroenterology & Hepatology 2009; 3(3): 257 doi: 10.1586/egh.09.16
|
| 65 |
Grace Hui-Min Wu, Barbara J Boucher, Yueh-Hsia Chiu, Chao-Sheng Liao, Tony Hsiu-Hsi Chen. Impact of chewing betel-nut (Areca catechu) on liver cirrhosis and hepatocellular carcinoma: a population-based study from an area with a high prevalence of hepatitis B and C infections. Public Health Nutrition 2009; 12(1): 129 doi: 10.1017/S1368980008002073
|
| 66 |
David van der Poorten, Jacob George. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatology International 2007; 1(3): 343 doi: 10.1007/s12072-007-9011-8
|
| 67 |
|
| 68 |
Eugen Florin Georgescu, Reanina Ionescu, Mihaela Niculescu, Laurentiu Mogoanta, Liliana Vancica. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World Journal of Gastroenterology 2009; 15(8): 942-954 doi: 10.3748/wjg.15.942
|
| 69 |
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology 2013; 19(4): 325 doi: 10.3350/cmh.2013.19.4.325
|
| 70 |
John S Lubel, Chandana B Herath, Louise M Burrell, Peter W Angus. Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications. Journal of Gastroenterology and Hepatology 2008; 23(9): 1327 doi: 10.1111/j.1440-1746.2008.05461.x
|
| 71 |
William Peverill, Lawrie Powell, Richard Skoien. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. International Journal of Molecular Sciences 2014; 15(5): 8591 doi: 10.3390/ijms15058591
|
| 72 |
Paul Manka, Amos Zeller, Wing-Kin Syn. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019; 79(9): 903 doi: 10.1007/s40265-019-01126-9
|
| 73 |
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano, Tooru Shimosegawa. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Journal of Gastroenterology 2015; 50(4): 364 doi: 10.1007/s00535-015-1050-7
|
| 74 |
John Richard, Ildiko Lingvay. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Review of Cardiovascular Therapy 2011; 9(3): 321 doi: 10.1586/erc.11.15
|
| 75 |
S. Gitto, G. Vitale, E. Villa, P. Andreone. Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future. Gastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/732870
|
| 76 |
Diana Barb, Paola Portillo-Sanchez, Kenneth Cusi. Pharmacological management of nonalcoholic fatty liver disease. Metabolism 2016; 65(8): 1183 doi: 10.1016/j.metabol.2016.04.004
|
| 77 |
Barham K. Abu Dayyeh, May Yang, Jules L. Dienstag, Raymond T. Chung. The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort. Digestive Diseases and Sciences 2011; 56(2): 564 doi: 10.1007/s10620-010-1507-8
|
| 78 |
T. T. Gordon-Walker, A. Pellicoro, J. P. Iredale. Liver under Constant Attack — From Fat to Viruses. 2009; : 141 doi: 10.1007/978-90-481-2759-7_15
|
| 79 |
Dawn M. Torres, Stephen A. Harrison. Diagnosis and Therapy of Nonalcoholic Steatohepatitis. Gastroenterology 2008; 134(6): 1682 doi: 10.1053/j.gastro.2008.02.077
|
| 80 |
J. S. Lubel, C. B. Herath, E. Velkoska, D. J. Casley, L. M. Burrell, P. W. Angus. Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research. Cytotechnology 2008; 58(3): 119 doi: 10.1007/s10616-009-9185-0
|
| 81 |
Mariana Verdelho Machado, Helena Cortez-Pinto. Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology 2014; 20(36): 12956-12980 doi: 10.3748/wjg.v20.i36.12956
|
| 82 |
Mariana Machado, Pedro Marques-Vidal, Helena Cortez-Pinto. Hepatic histology in obese patients undergoing bariatric surgery. Journal of Hepatology 2006; 45(4): 600 doi: 10.1016/j.jhep.2006.06.013
|